While this initial study is the simplest way of deciphering the individual metabolic benefits of GIPR agonism versus GIPR antagonist, a thorough metabolic comparison of a combinatorial approach (including assessments beyond just body weight) is vital for the advancement of personalised obesity research. The gene discussed is GIPR; the disease is obesity due to melanocortin 4 receptor deficiency.